Specify a stock or a cryptocurrency in the search bar to get a summary
Nuformix plc
NFXNuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom. Address: 60 Gracechurch Street, London, United Kingdom, EC3V 0HR
Analytics
WallStreet Target Price
770.53 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures NFX
Dividend Analytics NFX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NFX
Stock Valuation NFX
Financials NFX
Results | 2019 | Dynamics |